Author:
Sidorenko Valeria,Scodeller Pablo,Uustare Ain,Ogibalov Ivan,Tasa Andrus,Tshubrik Olga,Salumäe Liis,Sugahara Kazuki N.,Simón-Gracia Lorena,Teesalu Tambet
Funder
Ministerio de Ciencia e Innovación
Sihtasutus Archimedes
European Regional Development Fund
Eesti Teadusagentuur
EuroNanoMed III
TRANSCAN3
Publisher
Springer Science and Business Media LLC
Reference87 articles.
1. Siemann, D. W. et al. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 11, 416–420 (2005).
2. Siemann, D. W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat. Rev. https://doi.org/10.1016/j.ctrv.2010.05.001 (2011).
3. Dark, G. G. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829–1834 (1997).
4. Vincent, L. et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Investig. 115, 2992–3006. https://doi.org/10.1172/JCI24586 (2005).
5. Dowlati, A. et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62, 3408–3416 (2002).